Perspectives
Biologics dominate treatment costs for Crohn’s and ulcerative colitis
BIologic drug therapy makes up more than 70% of the total cost of care for either condition
October 19, 2019Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)
Crohn’s disease and ulcerative colitis are the two major types of inflammatory bowel disease (IBD). This study determined that biologic therapy makes up most of the annual total pharmacy and medical costs. It shows real-world prevalence, utilization, and total health care costs to improve understanding of the conditions. It adds Prime’s insights to the industry dialogue tying drug cost to value. But it’s clear that it is not possible to obtain a direct medical care cost offset to biologic therapy in IBD.
Related news
Perspectives
April 17, 2024
AMCP 2024: Behind the research with YuQian Liu
Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier
Perspectives
April 16, 2024
AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea
Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients
Perspectives
April 15, 2024
Oncology Insights: Cancer treatment is personal
Precision medicine, or personalized medicine, uses genes or proteins to diagnose or treat disease. This medical care design has significantly impacted oncology and grew out of a need to improve and individualize patient treatments